Shahram Paydar: TXA in Elderly Trauma: A Game-Changer for Endothelial Protection?
Shahram Paydar, Professor of Surgery and Trauma Surgeon, Consultant at Gulf Specialized Hospital, shared on LinkedIn:
“TXA in Elderly Trauma: A Game-Changer for Endothelial Protection? New Evidence Says Yes!
Trauma doesn’t discriminate by age, but outcomes do—especially for our older adults, who make up nearly 25% of admissions yet face steeper morbidity and mortality. Enter tranexamic acid (TXA): We know it’s a staple for bleeding control in TBI and hemorrhage, but a fresh 2025 analysis in J Trauma Acute Care Surg spotlights its extra punch in the ≥55 crowd.
Key findings from this secondary dive into the prehospital TXA-in-TBI database (n=436):
Despite similar injury severity (ISS ~20, head AIS ~3), older patients (mean 66y) showed sky-high admission endothelial biomarkers—thrombomodulin (↑17%), VCAM-1 (↑19%), angiotensin-2 (↑23%)—signaling pre-injury vulnerability.
The kicker?
2g prehospital TXA dampened these markers more dramatically in elders vs. younger folks (e.g., thrombomodulin p<0.00001, VCAM-1 p<0.0002 vs. placebo).
Younger subsets?
Less impact.
Why does this matter?
Endothelial dysfunction fuels the post-trauma inflammatory storm, and elders start from a weaker baseline. TXA’s amplified endothelial “shield” here could blunt hypercoagulability, reduce secondary hits, and—potentially—tip the scales on survival and recovery.
No direct mortality links yet (Level IV evidence), but it’s a clarion call: Standard TXA protocols might pack bigger benefits for our aging trauma wave.
As populations gray, this underscores TXA’s role beyond hemostasis—it’s endothelial insurance for the vulnerable.
Time to tweak protocols? Or wait for RCTs?
What’s your take—ramping up TXA emphasis in elder polytrauma? Share protocols or cases below!”
Title: Age matters: A Secondary Analysis of Endothelial Biomarkers in the Prehospital Tranexamic Acid for Traumatic Brain Injury Trial
Authors: Tanya Anand, Scott McLoud, Lindsay Loss, Karen Minoza, Phillip Jenkins, Susan Rowell, Jack McLean, Bellal Joseph, Martin Schreiber

Read the full article here.
Stay updated with Hemostasis Today.
-
Jul 16, 2026, 20:25Ilham Benzidia: Leaving ISTH 2026 With New Ideas and New Collaborations
-
Jul 16, 2026, 20:23Eman Hassan: A Fantastic Platelets and Megakaryocytes Session at ISTH 2026
-
Jul 16, 2026, 20:22Sankara Nelson Noah II: Investigating the Temporal Dynamics of Platelet – Leukocyte Interactions in Early Sepsis
-
Jul 16, 2026, 20:20Joseph Pierre Aboumsallem: Paris Certainly Delivered This Week, and Not Just Because of the Heat
-
Jul 16, 2026, 19:53Louise St. Germain Bannon: The End of Congress, the Beginning of New Collaborations
-
Jul 16, 2026, 19:18Steve Humphreys: Learning From the Leading Experts at ISTH 2026
-
Jul 16, 2026, 19:02Kellie Machlus: Where Science Meets Friendship at ISTH 2026
-
Jul 16, 2026, 18:51Aaron Paul Kithcart: When Clinical Research Comes Together at ISTH 2026
-
Jul 16, 2026, 18:40Sara Buonomo: Predicting Relapse in Immune-Mediated TTP at ISTH 2026